Concerning the degradation of β-blocker use in the 2018 ESC/ESH hypertension guidelines

Affiliations

¹ Cardiocentro "Ernesto Che Guevara", Medical University of Villa Clara, Villa Clara (VC), Cuba.
² Cardiometabolic Research Institute, Cardiology Section, 8181 Fannin St., Bldg. #3, Unit #314, Houston, TX 77054, USA.

Comment

Alberto Morales-Salinas et al. Eur Heart J. 2019.

. 2019 Jul 1;40(25):2091.

doi: 10.1093/eurheartj/ehz125.

¹ Cardiocentro "Ernesto Che Guevara", Medical University of Villa Clara, Villa Clara (VC), Cuba.
² Cardiometabolic Research Institute, Cardiology Section, 8181 Fannin St., Bldg. #3, Unit #314, Houston, TX 77054, USA.

No abstract available

Comment on

2018 ESC/ESH Guidelines for the management of arterial hypertension.
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group. Williams B, et al. Eur Heart J. 2018 Sep 1;39(33):3021-3104. doi: 10.1093/eurheartj/ehy339. Eur Heart J. 2018. PMID: 30165516 No abstract available.